Jurnalul de Chirurgie
 Jurnalul de chirurgie
Aparitie trimestriala in a doua luna a trimestrului
Published quarterly in the second month of the quarter
ISSN: 1584 - 9341 Vol.10 Nr.3 - Iulie-Septembrie 2014 | miercuri, 19 iunie 2019
ISSN: 1584 - 9341 Vol.10 No.3 - July-September 2014
British Flag| Romana Romanian Flag
Creditare EMC
Colegiul Medicilor
Va invitam sa va inregistrati/abonati la Jurnalul de chirurgie pentru a beneficia de creditare EMC


Tine minte
Ti-ai uitat parola?





Listare E-mail

L. Miron, M. Marinca
Department of Oncology, „St. Spiridon” Hospital Iaşi
University of Medicine and Pharmacy „Gr.T. Popa” Iaşi
Jurnalul de chirurgie 2008; 4 (2):72-77
Full text:
Format PDF (Română/Romanian)


Carcinoid tumors, composed of monotonous sheets of small round cell with uniform nuclei and cytoplasm, derive from the diffuse neuroendocrine system. Pathologists cannot differentiate benign from malignant tumors based on histology. Most commonly, carcinoid tumors occur in: the appendix (40%), small intestine (27%), rectum (13%) and bronchi (12%). Carcinoid tumors synthesize numerous bioactive amines and peptides, including neuron specific enolase (NSE), 5-hidroxitryptamine (serotonin), 5-hydroxytriptophan, synaptosin, chromogranin A and C, substance P, tachykinins, and hormones such as ACTH, calcitonin and growth hormone–releasing hormone. Serotonin causes the typical carcinoid syndrome, associated with severe flushing attacks. For all patients with carcinoid syndrome, the 5-year survival is approximately 25%. The prognosis varies with the site of origin and extent of disease. Surgery is useful for patients with localized primary carcinoids or metastatic tumors that produce obstruction. Control of liver metastases by surgery is associated with a 5-year survival of 80%. Recent data continue to document that chemotherapy has not been effective in gastro-pancreatic neuroendocrine tumors. Chemotherapy with doxorubycin, 5-fluorouracil and streptozocin has a 30% partial response rate. Somatostatin analogues, such as octreotide (Sandostatin) LAR in doses of 20-30 mg IM every 3 to 4 weeks, have been able to control signs and symptoms of carcinoid syndrome and appear to have decreased tumor growth, obtaining stabilization of disease.


Correspondence to: Lucian Miron, MD, PhD, Assoc. Prof., Depatment of Oncology, „St. Spiridon” Hospital Iaşi; Bd. Independenţei No. 1; 700111;
e-mail: ;

: Creative Commons License
Jurnalul de chirurgie [Journal of Surgery] by Editorial Board, Department of Surgery University of Medicine and Pharmacy Iasi, E. Tarcoveanu, R. Moldovanu is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Based on a work at www.jurnaluldechirurgie.ro.